Description

Depakin Enteric (Sodium Valproate) Coated Tablets 300 mg. №100

Ingredients

Active ingredient: Sodium valproate.
Other ingredients: Microcrystalline cellulose, maize starch, talc, colloidal anhydrous silica, povidone K30, methacrylic acid-ethyl acrylate copolymer, triethyl citrate, simethicone, macrogol 6000, titanium dioxide (E171), and iron oxide yellow (E172).

Dosage

Adults: The usual starting dose is 600 mg daily in divided doses. Dosage may be increased by 200 mg/day at weekly intervals. Maintenance dose ranges from 1 to 2 g daily.
Children: Dosage is weight-dependent. Consult a healthcare provider for appropriate dosing.

Indications

Depakin Enteric tablets are indicated for the treatment of epilepsy, bipolar disorder, and migraine prophylaxis.

Contraindications

Do not use Depakin Enteric tablets in patients with known hypersensitivity to sodium valproate or any of the excipients. It is contraindicated in patients with hepatic disease or urea cycle disorders.

Directions

Swallow the tablets whole with water. Do not crush or chew. Take with food to reduce gastrointestinal side effects.

Scientific Evidence

Sodium valproate, the active ingredient in Depakin Enteric, has been extensively studied for its efficacy in managing epilepsy and bipolar disorder. Research published in the *Journal of Clinical Psychopharmacology* demonstrated the effectiveness of sodium valproate in controlling manic episodes in bipolar disorder patients.

Additional Information

Depakin Enteric tablets should be stored at room temperature away from moisture and heat. Keep out of reach of children. Regular monitoring of liver function tests is recommended during treatment.

Pharmacological Effects:

Sodium valproate exerts its antiepileptic effects by increasing the brain’s levels of gamma-aminobutyric acid (GABA), an inhibitory neurotransmitter. This action helps to stabilize electrical activity in the brain, reducing the likelihood of seizures.

Clinical Trials and Comparative Effectiveness:

In a comparative study published in the *Journal of Neurology, Neurosurgery & Psychiatry*, sodium valproate was found to be as effective as carbamazepine in the treatment of focal and generalized epilepsies, with a similar side effect profile.